Delisting risk
Lexaria Bioscience
Developer and licensor of DehydraTECH oral drug-delivery technology.
$10.30
After-hours close−0.11 (−1.03%)
At close$10.41(−10.87%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 6.01%99.4K sharesInsiders 2.60%43.0K sharesOther 91.39%1.51M shares
Shares outstanding 1.65M · Float 1.60M · 97.0% free float
Institutions13F, as of Mar 31, 2026
28 holders · 99.4K shares · 10 new positions · 12 increased · 7 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Invenomic Capital Management LP | 29.5K | 1.78% | −1.9K | May 15, 2026 |
| Geode Capital Management, LLC | 19.6K | 1.19% | +5.0K | May 15, 2026 |
| Vanguard Capital Management LLC | 14.8K | 0.90% | +14.8Knew | May 15, 2026 |
| Toronto Dominion Bank | 9.3K | 0.56% | 0 | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 6.3K | 0.38% | +6.3Knew | May 8, 2026 |
| UBS Group AG | 3.5K | 0.21% | −20.6K | May 5, 2026 |
| State Street Corp | 2.6K | 0.16% | 0 | May 15, 2026 |
| BlackRock, Inc. | 1.8K | 0.11% | 0 | May 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Christopher Bunka | director | 37.0K | 2.24% | Mar 18, 2026 |
| Richard Christopher | director, officer: Chief Executive Officer | 4.3K | 0.26% | Jul 30, 2025 |
| William Edward McKechnie | director | 1.2K | 0.07% | Jul 30, 2025 |
| John Martin Docherty | director, officer: President & CSO | 358 | 0.02% | Jul 30, 2025 |
| Vanessa Carle | officer: Secretary | 50 | 0.00% | Jul 30, 2025 |
8 people have not refiled in the last 18 months (11.6K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.